Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Novo Nordisk and Oxford University to Further Enhance Diabetes Research

Published: Tuesday, November 05, 2013
Last Updated: Tuesday, November 05, 2013
Bookmark and Share
Partnership will establish a number of postdoctoral fellowship opportunities hosted by Oxford University and funded by Novo Nordisk.

Oxford University and Novo Nordisk announce the establishment of an international fellowship programme that aims to support the career and scientific development of young, exceptional research talent within diabetes. 

“We are honoured to establish the International PostDoctoral Fellowship Programme with Oxford University, which has such valuable expertise in the study and treatment of diabetes. By combining our company’s discovery and clinical development strengths with the research expertise and academic tradition of Oxford University, we can support the development of a new generation of exceptional diabetes researchers to eventually drive innovation further and improve the lives of the patients,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk.

As part of the agreement, a total of 12 young leading researchers will be offered a 3-year grant to support their research within the fields of diabetes, metabolism and endocrinology. The goal of the new programme is to support the development of a new generation of research leaders while further developing scientific excellence within diabetes. 

“This new programme will support the best young researchers doing novel work in the understanding of diabetes and its treatment. It is these early career researchers that will produce the new ideas, discoveries and advances that will improve diabetes treatment and care in the future. We’re delighted to partner with Novo Nordisk to provide this level of funding and support which will be important in enabling both their research and their career development,” said Professor Hugh Watkins of the Radcliffe Department of Medicine at Oxford University.

A joint steering committee with members from both Oxford University and Novo Nordisk will oversee the programme and assess research proposals from scientists at both organisations. 

The first four fellows in the programme will start in the autumn of 2014.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Introducing Novo Nordisk Pharmatech A/S
Novo Nordisk Pharmatech A/S is now a fully-fledged member of the Novo Nordisk family.
Friday, October 09, 2015
Novo Nordisk Buys New Hampshire Production Plant
Novo Nordisk announced the acquisition of a manufacturing facility in West Lebanon, New Hampshire, USA, from Olympus Biotech.
Thursday, August 28, 2014
Novo Nordisk Expects to Hire 6,000 Employees by 2022
Up to 2022, Novo Nordisk expects to hire 6,000 new employees in Denmark, half of whom will work within research and development.
Wednesday, June 11, 2014
Novo Nordisk Invests $100M in New Danish Purification Pilot Plant
Company increasing its drug development capacity by investing 550 million Danish kroner in a new research and development facility in Bagsværd, Denmark.
Monday, March 17, 2014
Novo Nordisk Receive Positive Opinions from the European Regulatory Authorities
The Committee for Medicinal Products for Human Use adopted positive opinions, recommending marketing authorisations, for Tresiba® and Ryzodeg® for the treatment of diabetes mellitus in adults.
Tuesday, October 23, 2012
Top researcher takes over as Director of the Protein Center
Jiri Lukas will join The Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen on 1 April.
Thursday, March 01, 2012
Novo Nordisk Establishes Type 1 Diabetes R&D Center in Seattle
The new center will combine Novo Nordisk's history in diabetes treatment with the company's growing expertise in immunotherapy.
Wednesday, January 25, 2012
Scientific News
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos